Neovascular (Wet) Age-related Macular Degeneration (nAMD)

DBCOND0158368Eye Disease Vascular Diseases

Neovascular (Wet) Age-related Macular Degeneration (nAMD) is the indication for 6 drugs in DrugBank. It is covered by 12 curated, structured indications.

Also known as: Wet Age-Related Macular Degeneration · "Wet" Age-Related Macular Degeneration · Neovascular Age-Related Macular Degeneration · Neovascular Age Related Macular Degeneration · Age-Related Neovascular Macular Degeneration
Classified under: Eye Disease
Vascular Diseases
Indicated drugs: Aflibercept
Bevacizumab
Brolucizumab
Faricimab
Pegaptanib
Ranibizumab

Resolves to

Vocabularies

ICD-10H35.32SNOMED CT11290001MedDRA10015902UMLSC0271084

What you can answer from here — as of September 29, 2026

6Indicated drugsWith each drug's targets and mechanism

Listed above

12Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

332Clinical trialsPhase, status and sponsor resolved per trial

5Drugs reporting it as an adverse effectWith incidence where the label states it

Which approved drugs for Neovascular (Wet) Age-related Macular Degeneration (nAMD) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account